KLRG1 and neoplasm: The study showed that this recombinant OV suppressed the antiviral cytotoxicity of KLRG1+ NK cells by approximately 50%, thus providing sufficient time for OV-CDH1 to complete viral replication, initiate secondary infection, and increase the tumor-killing potency.